Up 200% in 6 months, guess which ASX All Ords stock just hit another all-time high

This All Ords stock has made its investors very rich in recent months…

One ASX All Ordinaries Index (ASX: XAO) stock has returned more than 200% to its investors over the past six months alone. Today, it celebrated a second feat by hitting another new all-time high.

Which ASX All Ords company? That would be Clarity Pharmaceuticals Ltd (ASX: CU6). Yes, it was only in early November last year that Clarity shares were trading at $1.06 each. Today, those same shares will set an investor back $3.27.

As mentioned, this Thursday also saw Clarity hit a new record high. Just after the market opened this morning, the All Ords pharmaceutical stock hit $3.31, its new all-time record.

Lab worker puts hands in the air and dances around.

Image source: Getty Images

Why has this ASX All Ords stock just hit a new record high?

Here at the Motley Fool, we've been tracking Clarity's rising star over most of the year. Back in January, my Fool colleague analysed Frazis Capital portfolio manager Michael Frazis's view on the company.

Frazis presciently called Clarity "the most exciting company I've come across in Australia lately", thanks to the favourable data surrounding its copper therapy treatment for late-stage prostate cancer.

Frazis also argued that the company remained vastly undervalued compared to its potential:

If their data continues to hold, this is still early days, and it remains a fraction of the value of recent acquisitions in the space with early stage data.

In March, we also discussed ASX broker Bell Potter's optimistic view on Clarity Pharmaceuticals. Bell Potter posited similar sentiments to Frazis, noting Clarity's prostate cancer patient's having "apparently with no disease progression, many months after commencing treatment".

At the time, Bell Potter gave the All Ords stock a 'speculative buy' rating alongside a share price target of $3.25. That target has certainly aged well.

It was only earlier this week that Clarity revealed its first patient to be dosed with two cycles of its treatment achieved "a complete response", with "undetectable levels of prostate specific antigen (PSA) for almost 6 months".

Much of Clarity's share price gains have come since this positive announcement. Since Monday this week, this ASX All Ords stock has gained a whopping 26.4%. Let's see where this exciting company is headed next.

Motley Fool contributor Sebastian Bowen has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Happy businessman fist pumping while looking at a tablet.
Healthcare Shares

Up 13%: Why is everyone buying Pro Medicus shares this week?

The ASX healthcare shares jumped another 3% on Wednesday.

Read more »

healthcare worker overseeing group of aged care residents at table
Healthcare Shares

Regis Healthcare vs Ryman Healthcare: Which under-the-radar ASX small-cap could double from here?

We compare Regis Healthcare and Ryman Healthcare shares to find out which aged care small-cap could bounce back faster.

Read more »

Smiling female CEO with arms crossed stands in office with co-workers in background.
Healthcare Shares

CSL names Deborah Waterhouse as next CEO in global search

CSL has appointed Deborah Waterhouse as its next CEO, signalling continuity and experience as it moves into its next growth…

Read more »

A sad looking scientist sitting and upset about a share price fall.
Healthcare Shares

Telix shares crashing 8% today: What happened?

Find out what is going on with the ASX healthcare shares today.

Read more »

An older woman tries to listen by cupping her ear.
Healthcare Shares

Cochlear shares jump 9% in a week: Can they break past $150?

The shares are climbing higher into the green again on Wednesday.

Read more »

A senior pharmacist talks to a customer at the counter in a shop.
Healthcare Shares

Sigma Healthcare provides Chemist Warehouse sales update

Sigma Healthcare is in focus following strong double-digit Chemist Warehouse sales growth locally and overseas.

Read more »

Happy doctor using her laptop.
Healthcare Shares

Telix Pharmaceuticals Q3 2026 earnings: revenue up, pipeline advances

Telix Pharmaceuticals' Q3 2026 update sees strong revenue growth, FDA milestones, and a major merger to expand its radiopharmaceuticals platform.

Read more »

A young woman sits with her hand to her chin staring off to the side thinking about her investments.
Opinions

CSL shares: I weighed up the bull and bear case, and here's my final verdict

The ASX biotech company has rebounded strongly from a multi-year low in June.

Read more »